Historical Stock Price
AIM historical stock prices picture
AIM ImmunoTech (AIM) has the following price history information. Looking back at AIM historical stock prices for the last five trading days, on November 29, 2021, AIM opened at $1.43, traded as high as $1.48 and as low as $1.39, and closed at $1.44. Trading volume was a total of 435.50K shares. On November 30, 2021, AIM opened at $1.44, traded as high as $1.47 and as low as $1.41, and closed at $1.47. Trading volume was a total of 325.80K shares. On December 01, 2021, AIM opened at $1.47, traded as high as $1.51 and as low as $1.41, and closed at $1.41. Trading volume was a total of 244.90K shares. On December 02, 2021, AIM opened at $1.40, traded as high as $1.44 and as low as $1.35, and closed at $1.41. Trading volume was a total of 261.20K shares. On December 03, 2021, AIM opened at $1.41, traded as high as $1.41 and as low as $1.28, and closed at $1.32. Trading volume was a total of 324.60K shares.

AIM Historical Stock Prices By Date:

AIM historical cagr picture

Below, we examine the compound annual growth rate — CAGR for short — of an investment into AIM ImmunoTech shares, starting with a $10,000 purchase of AIM, and working forward through the historical stock price information to today.

Growth of $10,000.00
Without Dividends Reinvested

Start date: 12/06/2011
End date: 12/03/2021
Start price/share: $0.25
End price/share: $1.32
Dividends collected/share: $0.00
Total return: 428.00%
Average Annual Total Return: 18.10%
Starting investment: $10,000.00
Ending investment: $52,783.60
Years: 10.00
Date Open High Low Close Volume
11/29/2021 $1.43 $1.48 $1.39 $1.44 435.50K
11/30/2021 $1.44 $1.47 $1.41 $1.47 325.80K
12/01/2021 $1.47 $1.51 $1.41 $1.41 244.90K
12/02/2021 $1.40 $1.44 $1.35 $1.41 261.20K
12/03/2021 $1.41 $1.41 $1.28 $1.32 324.60K
AIM ImmunoTech is an immuno-pharma company that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Co.'s primary pharmaceutical product platform consists of Ampligen® and Alferon N Injection®. Ampligen® is approved for sale in Argentina for severe Chronic Fatigue Syndrome (CFS) and is an experimental drug in the U.S. undergoing clinical development for the treatment of certain cancers and myalgic encephalomyelitis/CFS. Alferon® is a natural-source, multi-species alpha interferon for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Date Close
11/29/2021$1.44
11/30/2021$1.47
12/01/2021$1.41
12/02/2021$1.41
12/03/2021$1.32
AIM is categorized under the Services sector; below are some other companies in the same sector:

ALCS Historical Stock Prices
AMBO Historical Stock Prices
AMC Historical Stock Prices
AMCN Historical Stock Prices
AMCX Historical Stock Prices
AMMA Historical Stock Prices
AMRK Historical Stock Prices
AMZN Historical Stock Prices
AN Historical Stock Prices
ANDE Historical Stock Prices

Email EnvelopeFree AIM Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts


AIM Historical Stock Prices | www.HistoricalStockPrice.com | Copyright © 2013 - 2021, All Rights Reserved

Nothing in www.HistoricalStockPrice.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.